Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 2/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | QDPR | P09417 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25585276 | 0.92 | SLC18A3 (0.47) | KDM1AP2RY14SLC18A3EPHX2EPHX1 | |
| SCHEMBL25831010 | 0.86 | SLC18A3 (0.47) | KDM1AP2RY14SLC18A3KCNH2 | |
| SCHEMBL8414100 | 0.84 | P2RY14 (0.47) | KDM1AP2RY14EPHX2EPHX1NAMPT | |
| SCHEMBL20705482 | 0.84 | RAB9A (0.50) | KDM1AP2RY14SLC18A3NAMPTTLR9 | |
| SCHEMBL571141 | 0.84 | KDM1A (0.60) | KDM1AP2RY14RIPK1RBP4KCNH2 | |
| Hydrochloric Acid SCHEMBL7511725 | 0.83 | KDM1A (0.43) | KDM1AP2RY14EPHX2EPHX1NAMPT | |
| SCHEMBL31488868 | 0.83 | NAMPT (0.58) | SLC18A3NAMPTTLR9TLR8TLR7 | |
| SCHEMBL15254117 | 0.83 | P2RY14 (0.56) | KDM1AP2RY14NAMPTRIPK1TLR9 | |
| SCHEMBL5695210 | 0.82 | CA2 (0.59) | KDM1AP2RY14CYP3A4CYP2C9SLC9A1 | |
| SCHEMBL571076 | 0.82 | P2RY14 (0.45) | KDM1AP2RY14EPHX2EPHX1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023083194-A1 | WEE1 PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF | 杭州格博生物医药有限公司 | 2023-05-19 | — | — | WO | disclosed |
| US-8575153-B2 | Pyridine-3-carboxyamide derivative | KOWA COMPANY, LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-2380877-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | Kowa Company, Ltd. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-1020434-A1 | 3-AMIDINOANILINE DERIVATIVES, ACTIVATED BLOOD COAGULATION FACTOR X INHIBITORS, AND INTERMEDIATES FOR PRODUCING BOTH | Kissei Pharmaceutical Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-6051580-A | Substituted heterocycles | ZENECA LIMITED | 2000-04-18 | — | — | US | disclosed |
| US-5880284-A | HAVING ANTITHROMBOTIC, ANTIAGGREGATORY AND TUMOR- OR METASTASES-INHIBITING EFFECTS | DR. KARL THOMAE GMBH (DE) | 1999-03-09 | — | — | US | disclosed |
| US-5681841-A | PREVENTION CELL AGGREGATION | KARL THOMAE GMBH (DE) | 1997-10-28 | — | — | US | disclosed |
| EP-0604800-A1 | 4- 4- 4-(carboxyalkyl)-phenyl amino carbonyl -phenyl -piperedines as aggregation inhibitors | Dr. Karl Thomae GmbH (DE) | 1994-07-06 | — | — | EP | disclosed |
| EP-0587134-A2 | Cyclic urea derivatives, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | JAK3, JAK1, UACA | KDM1A 465/4885P2RY14 2195/4885SLC18A3 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.